- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00304395
Pulmonary Infections Masquerading as Community-Acquired Pneumonia
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Guidelines to treat community acquired pneumonia (CAP) have been developed and widely promulgated by important professional societies in the past 10 years. The impetus to do so came from the observation that practicing physicians were using a wide array of approaches to this common infection, many of which were substandard.
The Infectious Disease Society of America (IDSA) and American Thoracic Society (ATS) have been leaders in this field, publishing recommendations separately between 1993 and 2003. The PI served on the IDSA committee and coauthored the publication in 2000 and the update in 2003. In 2004, a decision was made by the two professional societies to merge the committees and make a single joint set of recommendations; the PI is a member of that joint committee and a new document is being prepared for publication.
The PI has observed a tendency to apply these guidelines to cases that might masquerade as CAP but are actually attributable to other conditions, such as lung cancer, tuberculosis and histoplasmosis. Further, the recommendations do not adequately cover pneumonia due to Staphylococcus aureus.
The purpose of the research is to identify cases from the consult records of the Infectious Disease Section at the VAMC, Houston, and to compare them with other cases of CAP in order to determine whether there are features that might enable non-CAP cases to be distinguished from CAP.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Michael E. DeBakey Veterans Affairs Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- subjects who were seen in calendar year 2004 because they were thought to have CAP, but who, upon further evaluation, plainly did not, and consultation was sought.
- case control is diagnosis of CAP with verification by all or nearly all of the following features: presence of cough, increased sputum, fever, leukocytosis and a distinct new pulmonary infiltrate.
Exclusion Criteria:
- among the case controls, if the diagnosis of CAP was made despite the absence of the cardinal features of CAP, as cited above, the investigators will not include the case.
Studieplan
Hur är studien utformad?
Designdetaljer
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Daniel M Musher, M.D., Baylor College of Medicine, Houston VA Medical Center
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- H-17555
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Lunginflammation
-
National Institute of Allergy and Infectious Diseases...AvslutadHIV-infektioner | Pneumoni, Pneumocystis CariniiFörenta staterna
-
Glaxo WellcomeAvslutadHIV-infektioner | Pneumoni, Pneumocystis CariniiFörenta staterna
-
National Institute of Allergy and Infectious Diseases...AvslutadHIV-infektioner | Pneumoni, Pneumocystis CariniiFörenta staterna, Tanzania
-
National Institute of Allergy and Infectious Diseases...Jacobus Pharmaceutical; Glaxo WellcomeAvslutadHIV-infektioner | Pneumoni, Pneumocystis CariniiFörenta staterna
-
National Institute of Allergy and Infectious Diseases...Jacobus Pharmaceutical; Fujisawa Pharmaceutical CoAvslutadHIV-infektioner | Pneumoni, Pneumocystis CariniiFörenta staterna
-
National Institute of Allergy and Infectious Diseases...Fujisawa Pharmaceutical CoAvslutadHIV-infektioner | Pneumoni, Pneumocystis CariniiFörenta staterna, Puerto Rico
-
National Institute of Allergy and Infectious Diseases...AvslutadHIV-infektioner | Pneumoni, Pneumocystis CariniiFörenta staterna, Puerto Rico
-
National Institute of Allergy and Infectious Diseases...AvslutadHIV-infektioner | Pneumoni, Pneumocystis CariniiFörenta staterna, Puerto Rico
-
National Institute of Allergy and Infectious Diseases...Glaxo WellcomeAvslutadHIV-infektioner | Pneumoni, Pneumocystis CariniiFörenta staterna
-
National Institute of Allergy and Infectious Diseases...AvslutadHIV-infektioner | Pneumoni, Pneumocystis CariniiFörenta staterna